Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOCALIN XR vs QUILLICHEW ER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
Attention Deficit Hyperactivity Disorder (ADHD) (FDA-approved)
Attention Deficit Hyperactivity Disorder (ADHD)
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For Quilli Chew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Primarily metabolized via de-esterification to the major inactive metabolite d-ritalinic acid. Minor pathways include hydroxylation and oxidation, mediated by cytochrome P450 enzymes (CYP2D6, CYP3A4 are not major contributors).
Methylphenidate is primarily metabolized by deesterification via carboxylesterase 1 (CES1) to ritalinic acid, which is pharmacologically inactive. Minor metabolism via hydroxylation and microsomal oxidation.
Renal (approximately 90% as unchanged drug and metabolites)
Quilli Chew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Protein binding: ~15%, primarily to albumin
Methylphenidate is approximately 10-33% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
Vd: 1.5 L/kg
Volume of distribution (Vd) for methylphenidate is approximately 2-3 L/kg, indicating extensive tissue distribution. It is not highly bound to tissues.
Oral: 95% (FOCALIN XR)
Oral bioavailability of methylphenidate is variable and low, approximately 11-52% due to extensive first-pass metabolism. Quilli Chew ER is designed to deliver a consistent extended-release profile with a bioavailability of about 20-30% relative to immediate-release formulations.
GFR 30-89 m L/min: no adjustment. GFR <30 m L/min: reduce dose by 50%. Hemodialysis: administer after dialysis.
No dosage adjustment recommended for GFR >30 m L/min; avoid in GFR ≤30 m L/min.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Children ≥6 years: initial 5-10 mg orally once daily; increase by 5-10 mg weekly; max 60 mg/day. Weight-based: 0.3-0.5 mg/kg/day.
Children ≥6 years: initial 20 mg orally once daily, titrate by 10 mg weekly to max 60 mg/day.
Start at 5 mg orally once daily; increase slowly; monitor for cardiovascular effects and insomnia.
Start at 10 mg orally once daily, titrate cautiously; monitor for increased sensitivity and cardiovascular effects.
Focalin XR has a high potential for abuse and dependence. Prolonged use may lead to tolerance, psychological dependence, and withdrawal effects. It should be prescribed cautiously, especially in patients with a history of substance abuse.
QUILLICHEW ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: monitor for tachycardia and hypertension.,Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, new psychotic or manic symptoms, aggression.,Seizures: use with caution in patients with seizure disorders.,Long-term suppression of growth: monitor height and weight in pediatric patients.,Peripheral vasculopathy, including Raynaud's phenomenon.,Serotonin syndrome: risk when co-administered with serotonergic drugs.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; monitor closely.,Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, or aggressive behavior.,Long-term suppression of growth (weight and height) in pediatric patients.,Seizures: use with caution in patients with history of seizures.,Priapism: prolonged, painful erections may occur.,Peripheral vasculopathy: Raynaud's phenomenon.
Hypersensitivity to dexmethylphenidate or any component of the formulation.,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis risk).,Glaucoma.,Motor tics or family history of Tourette's syndrome.,Severe anxiety, tension, agitation.,Patients with a history of drug dependence or alcoholism.
Known hypersensitivity to methylphenidate or any component of the formulation.,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.,Glaucoma.,Motor tics or family history of Tourette's syndrome.,Severe anxiety, tension, or agitation.,Patients with history of drug abuse or dependence.
Avoid high-fat meals around the time of administration, as fat delays Tmax and reduces peak concentration. Avoid alcohol, which can disrupt the extended-release mechanism and lead to a sudden dose dump. Grapefruit juice may inhibit CYP2D6 and potentiate effects; limit or avoid consumption.
Avoid high-fat meals as they may delay absorption and alter peak concentration. Grapefruit and grapefruit juice may increase methylphenidate levels and should be avoided. Acidic foods (e.g., citrus fruits, colas) can affect drug absorption; maintain a consistent dietary pattern. Alcohol may cause dose dumping and should be avoided.
Pregnancy Category C. First trimester: Insufficient human data; animal studies show increased fetal resorptions and skeletal abnormalities at high doses. Second/third trimesters: Risk of preterm delivery, low birth weight, and neonatal withdrawal (irritability, dysphoria). Use only if benefit justifies risk.
Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (including irritability, dysphoria, and poor feeding).
No human data; M/P ratio unknown. Methylphenidate is excreted into breast milk in small amounts; potential for infant agitation and insomnia. Not recommended during breastfeeding.
Limited data. Methylphenidate is excreted into breast milk. M/P ratio not established. Infant relative dose <1% of maternal weight-adjusted dose. Monitor infant for agitation, insomnia, and poor weight gain. Avoid use in breastfeeding unless clearly necessary.
Pharmacokinetic changes: Increased clearance and volume of distribution may require dose adjustments. Start at lowest effective dose; consider dose increase if symptoms worsen. Postpartum: Decrease dose as clearance normalizes.
Physiologic changes in pregnancy (increased plasma volume, renal clearance, and hepatic metabolism) may reduce methylphenidate levels. Consider increasing dose based on clinical response and tolerability, with gradual titration. Monitor for reduced efficacy in second and third trimesters. Use lowest effective dose.
Focalin XR (dexmethylphenidate extended-release) uses the SODAS (Spheroidal Oral Drug Absorption System) delivery platform providing bimodal release. Avoid concurrent use with MAOIs or within 14 days of discontinuation. Monitor for growth suppression in children, weight loss, and insomnia. May exacerbate tics, anxiety, and psychosis. Not recommended for patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias. Use with caution with pressor agents and anticoagulants. The XR capsule may be opened and contents sprinkled on applesauce for patients with swallowing difficulties; all beads must be swallowed intact without crushing or chewing.
QUILLICHEW ER is an extended-release formulation of methylphenidate, a CNS stimulant, indicated for ADHD. Chewing or crushing the tablet destroys the extended-release mechanism, risking dose dumping. The tablet shell may appear in stool but is not medically significant. Monitor for growth suppression in children, weight loss, and potential for abuse. Avoid use in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Use caution in patients with hypertension, tachycardia, or pre-existing psychiatric disorders like bipolar disorder or psychosis. Assess for potential drug interactions, particularly with MAOIs, anticoagulants (may decrease effect), and vasopressors.
Take exactly as prescribed; do not crush, chew, or divide the capsule.,If you have trouble swallowing, you may open the capsule and sprinkle the beads on a spoonful of applesauce; swallow immediately without chewing.,Avoid taking with high-fat meals as they may delay absorption.,Do not take within 6 hours of bedtime to prevent insomnia.,Avoid alcohol as it can alter the release mechanism and increase side effects.,Notify your doctor if you experience chest pain, shortness of breath, palpitations, or fainting.,Report any new or worsening mental health symptoms such as aggression, hallucinations, or mania.,Monitor weight and height in children; appetite loss is common.,Store at room temperature, away from moisture and heat.,Keep out of reach of children; dependence and abuse are possible.
Take exactly as prescribed. Do not chew, crush, or split the tablet; swallow whole with liquid.,The tablet shell may appear in your stool, but the medication is absorbed; this is normal.,Do not take in the evening to prevent insomnia. Take in the morning with or without food.,Avoid alcohol while taking this medication; alcohol can affect the extended-release properties.,Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache.,Report any chest pain, shortness of breath, fainting, or severe dizziness immediately.,Store at room temperature, protect from moisture, and keep out of reach of children.,Your doctor will monitor your blood pressure, heart rate, and weight regularly.,Do not stop abruptly; tapering may be needed to avoid withdrawal or rebound depression.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOCALIN XR vs QUILLICHEW ER, answered by our medical review team.
FOCALIN XR is a CNS Stimulant that works by Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.. QUILLICHEW ER is a CNS Stimulant that works by Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOCALIN XR and QUILLICHEW ER depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOCALIN XR is: Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.. The standard adult dose of QUILLICHEW ER is: Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOCALIN XR and QUILLICHEW ER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOCALIN XR is classified as Category C. Pregnancy Category C. First trimester: Insufficient human data; animal studies show increased fetal resorptions and skeletal abnormalities at high doses. Second/third trimesters: R. QUILLICHEW ER is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.